Differential role of three major New Zealand Black-derived loci linked with Yaa-induced murine lupus nephritis.
By assessing the development of Y-linked autoimmune acceleration (Yaa) gene-induced systemic lupus erythematosus in C57BL/6 (B6) x (New Zealand Black (NZB) x B6.Yaa)F(1) backcross male mice, we mapped three major susceptibility loci derived from the NZB strain. These three quantitative trait loci (QTL) on NZB chromosomes 1, 7, and 13 differentially regulated three different autoimmune traits: anti-nuclear autoantibody production, gp70-anti-gp70 immune complex (gp70 IC) formation, and glomerulonephritis. Contributions to the disease traits were further confirmed by generating and analyzing three different B6.Yaa congenic mice, each carrying one individual NZB QTL. The chromosome 1 locus that overlapped with the previously identified Nba2 (NZB autoimmunity 2) locus regulated all three traits. A newly identified chromosome 7 locus, designated Nba5, selectively promoted anti-gp70 autoantibody production, hence the formation of gp70 IC and glomerulonephritis. B6.Yaa mice bearing the NZB chromosome 13 locus displayed increased serum gp70 production, but not gp70 IC formation and glomerulonephritis. This locus, called Sgp3 (serum gp70 production 3), selectively regulated the production of serum gp70, thereby contributing to the formation of nephritogenic gp70 IC and glomerulonephritis, in combination with Nba2 and Nba5 in NZB mice. Among these three loci, a major role of Nba2 was demonstrated, because B6.Yaa Nba2 congenic male mice developed the most severe disease. Finally, our analysis revealed the presence in B6 mice of an H2-linked QTL, which regulated autoantibody production. This locus had no apparent individual effect, but most likely modulated disease severity through interaction with NZB-derived susceptibility loci.
Kikuchi
Shuichi
S
Department of Pathology and Immunology, Centre Médical Universitaire, Geneva, Switzerland.
Fossati-Jimack
Liliane
L
Moll
Thomas
T
Amano
Hirofumi
H
Amano
Eri
E
Ida
Akinori
A
Ibnou-Zekri
Nabila
N
Laporte
Catherine
C
Santiago-Raber
Marie-Laure
ML
Rozzo
Stephen J
SJ
Kotzin
Brian L
BL
Izui
Shozo
S
D000818:Animals; D000974:Antibodies, Antinuclear / Q000097:blood; D000936:Antigen-Antibody Complex / Q000097:blood; D001324:Autoantigens / Q000097:blood; D002843:Chromatin / Q000276:immunology; D003433:Crosses, Genetic; D008040:Genetic Linkage / Q000276:immunology*; D005819:Genetic Markers / Q000276:immunology; D020022:Genetic Predisposition to Disease; D005921:Glomerulonephritis / Q000235:genetics / Q000276:immunology; D006023:Glycoproteins / Q000097:blood / Q000235:genetics; D007074:Immunoglobulin G / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000235:genetics / Q000276:immunology; D008181:Lupus Nephritis / Q000235:genetics* / Q000276:immunology*; D008297:Male; D051379:Mice; D020297:Mice, Congenic; D008810:Mice, Inbred C57BL; D008814:Mice, Inbred NZB / Q000235:genetics*; D018832:Molecular Chaperones / Q000235:genetics; D009154:Mutation; D040641:Quantitative Trait Loci / Q000276:immunology*; D013577:Syndrome; D015854:Up-Regulation / Q000235:genetics / Q000276:immunology; D014998:Y Chromosome / Q000276:immunology*
D000974:Antibodies, Antinuclear; D000936:Antigen-Antibody Complex; D001324:Autoantigens; D002843:Chromatin; D005819:Genetic Markers; D006023:Glycoproteins; D007074:Immunoglobulin G; D018832:Molecular Chaperones; C479954:Sgp3 protein, mouse; C033589:glycoprotein gp70, murine serum